Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Jacobs, MD, MBA
Applied Genetics Technologies Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hadassah-Hebrew University Medical Center
Jerusalem, Israel
- Vitreoretinal Associates
Gainesville, Florida, United States
- Bascom Palmer Eye Institute
Miami, Florida, United States
- Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, United States
- Cincinnati Eye Institute
Cincinnati, Ohio, United States
- Casey Eye Institute, Oregon Health and Sciences University
Portland, Oregon, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Aug 2017
- Primary completion
- 31 Aug 2022
- Completion
- 31 Aug 2026
- Last update posted
- 22 Jul 2022
- Registered enrollment
- 24
- Registry id
- NCT02935517
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.